Amid an evolving landscape of anticancer agents, numerous approaches to elicit tumor-specific immune responses are under active investigation. In broad terms, these approaches have traditionally ...
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
• This study aimed to investigate the immunophenotype of esophageal cancer (ESCA) by assessing the patient’s immune defenses or autoimmune function and to identify potential tumor antigens and ...
Cancer vaccines have long promised a way to teach the immune system to hunt down tumors with the same precision it uses against viruses, but the promise has repeatedly collided with biology. Free ...
A research team has introduced a novel cancer immunotherapy strategy. This approach involves attaching "fake targets" to tumor cells to guide immune cell attacks, overcoming the limitations of ...
Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...
Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...
A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomas. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results